Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Role of electrophysiological studies in predicting risk of ventricular arrhythmia in early repolarization syndrome

S. Mahida, N. Derval, F. Sacher, A. Leenhardt, I. Deisenhofer, D. Babuty, J. Schläpfer, L. de Roy, R. Frank, S. Yli-Mayry, P. Mabo, T. Rostock, A. Nogami, JL. Pasquié, C. de Chillou, J. Kautzner, L. Jesel, P. Maury, B. Berte, S. Yamashita, L....

. 2015 ; 65 (2) : 151-9.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15013945

BACKGROUND: The early repolarization (ER) pattern is associated with an increased risk of arrhythmogenic sudden death. However, strategies for risk stratification of patients with the ER pattern are not fully defined. OBJECTIVES: This study sought to determine the role of electrophysiology studies (EPS) in risk stratification of patients with ER syndrome. METHODS: In a multicenter study, 81 patients with ER syndrome (age 36 ± 13 years, 60 males) and aborted sudden death due to ventricular fibrillation (VF) were included. EPS were performed following the index VF episode using a standard protocol. Inducibility was defined by the provocation of sustained VF. Patients were followed up by serial implantable cardioverter-defibrillator interrogations. RESULTS: Despite a recent history of aborted sudden death, VF was inducible in only 18 of 81 (22%) patients. During follow-up of 7.0 ± 4.9 years, 6 of 18 (33%) patients with inducible VF during EPS experienced VF recurrences, whereas 21 of 63 (33%) patients who were noninducible experienced recurrent VF (p = 0.93). VF storm occurred in 3 patients from the inducible VF group and in 4 patients in the noninducible group. VF inducibility was not associated with maximum J-wave amplitude (VF inducible vs. VF noninducible; 0.23 ± 0.11 mV vs. 0.21 ± 0.11 mV; p = 0.42) or J-wave distribution (inferior, odds ratio [OR]: 0.96 [95% confidence interval (CI): 0.33 to 2.81]; p = 0.95; lateral, OR: 1.57 [95% CI: 0.35 to 7.04]; p = 0.56; inferior and lateral, OR: 0.83 [95% CI: 0.27 to 2.55]; p = 0.74), which have previously been demonstrated to predict outcome in patients with an ER pattern. CONCLUSIONS: Our findings indicate that current programmed stimulation protocols do not enhance risk stratification in ER syndrome.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15013945
003      
CZ-PrNML
005      
20150428103203.0
007      
ta
008      
150420s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacc.2014.10.043 $2 doi
035    __
$a (PubMed)25593056
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mahida, Saagar $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France. Electronic address: saagar7m7@yahoo.co.uk.
245    10
$a Role of electrophysiological studies in predicting risk of ventricular arrhythmia in early repolarization syndrome / $c S. Mahida, N. Derval, F. Sacher, A. Leenhardt, I. Deisenhofer, D. Babuty, J. Schläpfer, L. de Roy, R. Frank, S. Yli-Mayry, P. Mabo, T. Rostock, A. Nogami, JL. Pasquié, C. de Chillou, J. Kautzner, L. Jesel, P. Maury, B. Berte, S. Yamashita, L. Roten, HS. Lim, A. Denis, P. Bordachar, P. Ritter, V. Probst, M. Hocini, P. Jaïs, M. Haïssaguerre,
520    9_
$a BACKGROUND: The early repolarization (ER) pattern is associated with an increased risk of arrhythmogenic sudden death. However, strategies for risk stratification of patients with the ER pattern are not fully defined. OBJECTIVES: This study sought to determine the role of electrophysiology studies (EPS) in risk stratification of patients with ER syndrome. METHODS: In a multicenter study, 81 patients with ER syndrome (age 36 ± 13 years, 60 males) and aborted sudden death due to ventricular fibrillation (VF) were included. EPS were performed following the index VF episode using a standard protocol. Inducibility was defined by the provocation of sustained VF. Patients were followed up by serial implantable cardioverter-defibrillator interrogations. RESULTS: Despite a recent history of aborted sudden death, VF was inducible in only 18 of 81 (22%) patients. During follow-up of 7.0 ± 4.9 years, 6 of 18 (33%) patients with inducible VF during EPS experienced VF recurrences, whereas 21 of 63 (33%) patients who were noninducible experienced recurrent VF (p = 0.93). VF storm occurred in 3 patients from the inducible VF group and in 4 patients in the noninducible group. VF inducibility was not associated with maximum J-wave amplitude (VF inducible vs. VF noninducible; 0.23 ± 0.11 mV vs. 0.21 ± 0.11 mV; p = 0.42) or J-wave distribution (inferior, odds ratio [OR]: 0.96 [95% confidence interval (CI): 0.33 to 2.81]; p = 0.95; lateral, OR: 1.57 [95% CI: 0.35 to 7.04]; p = 0.56; inferior and lateral, OR: 0.83 [95% CI: 0.27 to 2.55]; p = 0.74), which have previously been demonstrated to predict outcome in patients with an ER pattern. CONCLUSIONS: Our findings indicate that current programmed stimulation protocols do not enhance risk stratification in ER syndrome.
650    _2
$a dospělí $7 D000328
650    _2
$a náhlá srdeční smrt $x epidemiologie $x etiologie $x prevence a kontrola $7 D016757
650    _2
$a elektrokardiografie $x metody $7 D004562
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a převodní systém srdeční $x patofyziologie $7 D006329
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a míra přežití $x trendy $7 D015996
650    _2
$a časové faktory $7 D013997
650    _2
$a fibrilace komor $x komplikace $x diagnóza $x patofyziologie $7 D014693
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Derval, Nicolas $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France.
700    1_
$a Sacher, Frederic $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France.
700    1_
$a Leenhardt, Antoine $u AP-HP, Hôpital Bichat, Service de Cardiologie et Centre de Référence des Maladies Cardiaques Héréditaires, INSERM, U698, Université Paris Diderot, Paris, France.
700    1_
$a Deisenhofer, Isabel $u Deutsches Herzzentrum München, Munich, Germany.
700    1_
$a Babuty, Dominique $u Centre Hospitalier Universitaire de Tours, Tours, France.
700    1_
$a Schläpfer, Jürg $u Service de Cardiologie, CHUV, Lausanne, Switzerland.
700    1_
$a de Roy, Luc $u Clinique Mont Godinne Leuven, Leuven, Belgium.
700    1_
$a Frank, Robert $u Groupe Hospitalier Pitié Salpêtrière, Paris, France.
700    1_
$a Yli-Mayry, Sinikka $u Tampere University Hospital, Tampere, Finland.
700    1_
$a Mabo, Philippe $u Centre Hospitalier Universitaire de Rennes, Rennes, France.
700    1_
$a Rostock, Thomas $u Eppendorf Hospital, Hamburg, Germany.
700    1_
$a Nogami, Akihiko $u University of Tsukuba, Tsukuba, Japan.
700    1_
$a Pasquié, Jean-Luc $u Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
700    1_
$a de Chillou, Christian $u Centre Hospitalier Universitaire de Nancy, Nancy, France.
700    1_
$a Kautzner, Josef $u Institute for Clinical and Experimental Medicine, Department of Cardiology, Prague, Czech Republic.
700    1_
$a Jesel, Laurence $u Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.
700    1_
$a Maury, Philippe $u Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
700    1_
$a Berte, Benjamin $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France.
700    1_
$a Yamashita, Seigo $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France.
700    1_
$a Roten, Laurent $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France.
700    1_
$a Lim, Han S $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France.
700    1_
$a Denis, Arnaud $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France.
700    1_
$a Bordachar, Pierre $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France.
700    1_
$a Ritter, Philippe $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France.
700    1_
$a Probst, Vincent $u Centre Hospitalier Universitaire de Nantes, Nantes, France.
700    1_
$a Hocini, Mélèze $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France.
700    1_
$a Jaïs, Pierre $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France.
700    1_
$a Haïssaguerre, Michel $u Hôpital Cardiologique du Haut-Lévêque and Université Victor Segalen Bordeaux II, Bordeaux, France.
773    0_
$w MED00002964 $t Journal of the American College of Cardiology $x 1558-3597 $g Roč. 65, č. 2 (2015), s. 151-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25593056 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20150428103506 $b ABA008
999    __
$a ok $b bmc $g 1071526 $s 896823
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 65 $c 2 $d 151-9 $i 1558-3597 $m Journal of the American College of Cardiology $n J. Am. Coll. Cardiol. $x MED00002964
LZP    __
$a Pubmed-20150420

Najít záznam

Citační ukazatele

Možnosti archivace